Stockchase Opinions

The Panic-Proof Portfolio (Stockchase Research) BioNTech BNTX-Q TOP PICK Dec 21, 2023

Stockchase Research Editor: Michael O'Reilly

This $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment.  It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE.  Cash reserves are growing, while stock is bought back.  We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%.  Yield 0%  

(Analysts’ price target is $137.07)
$103.845

Stock price when the opinion was issued

Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)

BUY
He likes it. He hopes China's government buys their Covid vaccine.
PAST TOP PICK
(A Top Pick May 14/21, Down 28%) Has kept shares in company and likes the business model. Cash from vaccine sales will be used to make other vaccines and therapeutics. Long term is a good investment. Lots of R & D opportunities.
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The $28 billion biotech just received FDA approval of their updated COVID vaccine.  It trades at 6x earnings, 1.3x book and supports a 23% ROE.  We like that cash reserves are growing, while shares are bought back and debt is retired.   We recommend placing a stop-loss at $100, looking to achieve $161 -- upside potential of 40%.  Yield 0% 

(Analysts’ price target is $161.34)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 14/23, Down 13.2%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with ALC has triggered its stop at $14.50. To remain disciplined, we recommend covering the position at this time. 

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 21/23, Up 9.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with BNTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $78) to $95 at this time.